{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:19:26Z","timestamp":1788283166965,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009780","name":"Region Sk\u00e5ne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.msard.2025.106479","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:56:52Z","timestamp":1746061012000},"page":"106479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Comparison of CSF biomarkers in multiple sclerosis patients treated with natalizumab and rituximab"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1491-2003","authenticated-orcid":false,"given":"Johan","family":"Hellgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Ahlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Compagno","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus F\u00f6rnvik","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"K\u00e4ll\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106479_bib0001","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaneurol.2023.3997","article-title":"Neurofilament light chain elevation and disability progression in multiple sclerosis","volume":"80","author":"Abdelhak","year":"2023","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106479_bib0002","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1352458513490544","article-title":"Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis","volume":"20","author":"Axelsson","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106479_bib0003","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00415-010-5863-2","article-title":"Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis","volume":"258","author":"Axelsson","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106479_bib0004","article-title":"CSF neurofilament light chain predicts 10-year clinical and radiologic worsening in multiple sclerosis","volume":"7","author":"Bhan","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106479_bib0005","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1474-4422(08)70259-X","article-title":"Cognitive impairment in multiple sclerosis","volume":"7","author":"Chiaravalloti","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106479_bib0006","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/jamaneurol.2024.0017","article-title":"Emerging cerebrospinal fluid biomarkers of disease activity and progression in multiple sclerosis","volume":"81","author":"Cross","year":"2024","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106479_bib0007","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","article-title":"Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients","volume":"180","author":"Cross","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106479_bib0008","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/jnnp-2012-304695","article-title":"Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude","volume":"84","author":"Dobson","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106479_bib0009","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s00415-019-09398-7","article-title":"Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis","volume":"266","author":"Gaetani","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106479_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11122230","article-title":"Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis","volume":"11","author":"Ganapathy Subramanian","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.msard.2025.106479_bib0011","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B-cell therapy for multiple sclerosis: entering an era","volume":"83","author":"Greenfield","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106479_bib0012","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ana.22247","article-title":"Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab","volume":"69","author":"Gunnarsson","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106479_bib0013","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/13524585221134213","article-title":"Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis","volume":"29","author":"Hegen","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106479_bib0014","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ane.13225","article-title":"Rituximab in multiple sclerosis at general hospital level","volume":"141","author":"Hellgren","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2025.106479_bib0015","article-title":"A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab","volume":"10","author":"Hellgren","year":"2024","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106479_bib0016","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3389\/fneur.2020.00608","article-title":"A Score based on NfL and glial markers may differentiate between relapsing-remitting and progressive MS course","volume":"11","author":"Huss","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106479_bib0017","unstructured":"Johnsson M. Lumbalpunktion, Tillv\u00e4gag\u00e5ngss\u00e4tt, https:\/\/www.vardhandboken.se\/undersokning-och-provtagning\/biopsier-och-punktioner\/lumbalpunktion\/tillvagagangssatt\/(2023, accessed 2025-01-19 2025)."},{"key":"10.1016\/j.msard.2025.106479_bib0018","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/jnnp.2008.150896","article-title":"CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients","volume":"80","author":"Joseph","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106479_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102604","article-title":"A review of compartmentalised inflammation and tertiary lymphoid structures in the pathophysiology of multiple Sclerosis","volume":"10","author":"Kee","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.msard.2025.106479_bib0020","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1177\/1352458518769837","article-title":"The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: The case of multiple sclerosis","volume":"25","author":"Kobelt","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106479_bib0021","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/jnnp-2023-331784","article-title":"Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy","volume":"95","author":"Longinetti","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106479_bib0022","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1177\/1352458514538111","article-title":"Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study","volume":"20","author":"Mancuso","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106479_bib0023","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106479_bib0024","unstructured":"N Latex FLC kappa and lambda, rev 12 (Package Inserts), 2025 Siemens Healthineers, Erlangen, Germany."},{"key":"10.1016\/j.msard.2025.106479_bib0025","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s40120-023-00549-7","article-title":"No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: clinician and patient perspectives [Narrative Review]","volume":"12","author":"Newsome","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106479_bib0026","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/1352458516639384","article-title":"Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis","volume":"23","author":"Novakova","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106479_bib0027","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/archneurol.2010.99","article-title":"Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis","volume":"67","author":"Piccio","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2025.106479_bib0028","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ana.27012","article-title":"COMBAT-MS: a population-based observational cohort study addressing the benefit-risk balance of multiple sclerosis therapies compared with rituximab","volume":"96","author":"Piehl","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106479_bib0029","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106479_bib0030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13195-024-01457-0","article-title":"Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy","volume":"16","author":"Rasing","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.msard.2025.106479_bib0031","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","article-title":"Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment","volume":"101","author":"Rubenstein","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.msard.2025.106479_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1265354","article-title":"A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis","volume":"14","author":"Sandgren","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106479_bib0033","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001030","article-title":"Effects of natalizumab therapy on intrathecal immunoglobulin G production indicate targeting of plasmablasts","volume":"8","author":"Schl\u00fcter","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106479_bib0034","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000906","article-title":"Chitinase 3-like 1 and neurofilament light chain in CSF and CNS atrophy in MS","volume":"8","author":"Schneider","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106479_bib0035","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1002\/alz.12806","article-title":"Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: the effect of sample stability","volume":"18","author":"Simr\u00e9n","year":"2022","journal-title":"Alzheimers. Dement."},{"key":"10.1016\/j.msard.2025.106479_bib0036","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.80.7_supplement.P05.187","article-title":"Persistence of cerebrospinal fluid oligoclonal bands after natalizumab treatment in multiple sclerosis patients (P05.187)","volume":"80","author":"Stark","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106479_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102870","article-title":"A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta-analysis","volume":"51","author":"Sun","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106479_bib0038","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","article-title":"Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial","volume":"21","author":"Svenningsson","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106479_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135886","article-title":"Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction","volume":"10","author":"V\u00e5gberg","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2025.106479_bib0040","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P02.136","article-title":"Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients (P02.136)","volume":"78","author":"Von Glehn Silva","year":"2012","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:40:33Z","timestamp":1762602033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825002214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":40,"alternative-id":["S2211034825002214"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106479","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of CSF biomarkers in multiple sclerosis patients treated with natalizumab and rituximab","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106479"}}